within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J07C_BacterialAndViralVaccinesCombined.J07CA10_TyphoidHepatitisA;

model TyphoidHepatitisA
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 0,
    adminDuration = 600,
    adminMass = 1 / 1000000,
    adminCount = 1,
    Vd = 0.001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>TyphoidHepatitisA</td></tr><tr><td>ATC code:</td><td>J07CA10</td></tr><td>route:</td><td>intramuscular</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0</td><td></td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Combined typhoid and hepatitis A vaccine (ATC J07CA10) is used for immunization against both typhoid fever (caused by Salmonella typhi) and hepatitis A virus infection. It is a modern vaccine preparation often used for travelers to regions with risk for these infections and is an approved medication.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic (PK) studies with detailed PK parameter reporting for the combined typhoid-hepatitis A vaccine were identified. As this is an inactivated vaccine product, standard PK parameters like bioavailability, clearance, volume of distribution are generally not reported.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J07CA10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end TyphoidHepatitisA;
